Interferon-α is effective for CD4+, CCR4-mycosis fungoides

International Journal of Dermatology

Volumn 46, Issue 4, 2007, Pages 435-438

  Fujimura, Taku ^a   Okuyama, Ryuhei ^a   Watabe, Akiko ^a   Hashimoto, Akira ^a   Tagami, Hachiro ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; ETRETINATE; GAMMA INTERFERON; PEGINTERFERON; PSORALEN; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTRON THERAPY; ERYTHEMA; EYELID CANCER; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MYCOSIS FUNGOIDES; PUVA; RECURRENT CANCER; STEROID THERAPY; TH2 CELL;

ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; ERYTHEMA; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; RECEPTORS, CHEMOKINE;

EID: 34247133577     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03221.x     Document Type: Article

References (16)

1. Pichardo DA, Querfeld C, Guitart J, et al. Cutaneous T-cell lymphoma: A paradigm for biological therapies. Leukemia Lymphoma 2004; 45: 1755-1765.
2. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
3. O'garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 2000; 10: 542-550.
4. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-134.
5. Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002; 119: 1405-1410.
6. Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15: 431-439.
7. Fujimura T, Aiba S, Yoshino Y, et al. CCR4 expression by atypical T cells in systemic pilotrophic lymphoma: Its behavior under treatment with interferon gamma, topical PUVA and systemic retinoid. Dermatology 2004; 208: 221-226.
8. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-1060.
9. Fujimura T, Okuyama R, Hashimoto A, et al. Effective control of rush progression of CD8 positive mycosis fungoides with pegylated interferon. Acta Derm Venereol 2006; 86: 161-162.
10. Rook AH, McGinnis KS, Richardson SK, et al. The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 331-336.
11. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1089-1107.
12. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208-212.
13. Bunn PA Jr, Foon KA, Ihde DC, et al. Recombinant leucocyte A interferon: an active agent in advanced cutaneous T cell lymphoma. Ann Intern Med 1984; 101: 484-487.
14. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90-94.
15. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-673.
16. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta chain). Blood 1996; 88: 1383-1389.